Our upcoming Unlocking Innovation webinar analyzes dealmaking activity to identify mechanisms and technologies that have been trending in recent years, beyond ADCs or GLP-1s. While these two modalities have dominated headlines and investor interest, thanks to their blockbuster potential in oncology and metabolic disease, there’s a broader wave of innovation that could shape the future biopharmaceutical landscape.
The accompanying report, which will be available soon, dives deep into the patterns of Partnering Alliances and M&A activity to uncover the mechanisms and technologies shaping the future of medicine. And while antibody-drug conjugates (ADCs) and GLP-1 receptor agonists have dominated headlines, exciting opportunities lie in what’s trending beyond these blockbuster modalities.
By analyzing recent transactions and monitoring changes in deal activity in recent years, our report identifies therapeutic areas that are attracting serious investment and strategic interest.
These include:
- Immunomodulators: Recent deals emphasize next-gen immunotherapies targeting autoimmune disorders, oncology, and dermatology as well as platform technologies that enable broader immunomodulatory applications across multiple indications
- Gastro-intestinal: Strategic partnerships are expanding in the microbiome space, especially for conditions like irritable bowel syndrome (IBS) and ulcerative colitis.
- Respiratory: Major pharma players are expanding their respiratory portfolios through acquisitions and alliances focused on monoclonal antibodies targeting IL-4, IL-5, and TSLP pathways as well as rare respiratory diseases.
Regarding technologies, the deal landscape suggests a broader appetite for innovation:
- Recombinant Antibodies: Deal trends show strong momentum in bispecifics, ADCs, and platform-based collaborations, with oncology and immunology leading the charge.
- Plasma-Derived Therapies: Growth driven by rising demand for immunoglobulins, coagulation factors, and albumin products used in neurology, hematology, and critical care.
- RNA Therapeutics: Companies favor partnering on late-stage mRNA programs, thus reducing development risk, with deals often targeting cancer immunotherapies or rare diseases
The future of pharma will be driven by a combination of scientific innovation, strategic collaborations, and bold acquisitions. As companies look beyond ADCs and GLP-1s, they’re embracing diverse innovation portfolios, which could redefine how we treat diseases in the next decade.
If you’d like to explore the full landscape of emerging therapies and deal trends, our Unlocking Innovation webinar offers a data-driven roadmap to the future of biopharma. You can register here to join us on November 20th, at 3pm GMT/10am ET. I hope you see you there!
